Healthcare -
Biotechnology - NASDAQ - US
$ 1.6799
-2.05 %
$ 23.5 M
Market Cap
-1.06
P/E
1. INTRINSIC VALUE
Balance Sheet
CalciMedica, Inc.
| Current Assets | 19.7 M |
| Cash & Short-Term Investments | 18.7 M |
| Receivables | 0 |
| Other Current Assets | 996 K |
| Non-Current Assets | 129 K |
| Long-Term Investments | 0 |
| PP&E | 119 K |
| Other Non-Current Assets | 10 K |
| Current Liabilities | 3.68 M |
| Accounts Payable | 2 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 1.69 M |
| Non-Current Liabilities | 1.7 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 1.7 M |
EFFICIENCY
Earnings Waterfall
CalciMedica, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 24.2 M |
| Operating Income | -24.2 M |
| Other Expenses | -10.5 M |
| Net Income | -13.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CalciMedica, Inc.
| Net Income | -13.7 M |
| Depreciation & Amortization | 58 K |
| Capital Expenditures | -8 K |
| Stock-Based Compensation | 2.31 M |
| Change in Working Capital | -495 K |
| Others | -10.4 M |
| Free Cash Flow | -21.2 M |
Wall Street Analysts Price Targets
CalciMedica, Inc.
Wall Street analysts predict an average 1-year price target for CALC of $6 , with forecasts ranging from
a
low of
$2 to a high of $14 .
CALC Lowest Price Target
Wall Street Target
2 USD
19.05%
CALC Average Price Target
Wall Street Target
6 USD
257.16%
CALC Highest Price Target
Wall Street Target
14 USD
733.38%
4. DIVIDEND
ANALYSIS
CALC does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CalciMedica, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.22 M USD 5
6-9 MONTHS
467 K USD 3
9-12 MONTHS
7. News
CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade
CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 2 months ago
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
LA JOLLA, Calif. , April 1, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
prnewswire.com
- 2 months ago
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif. , March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2024 and provided clinical and corporate updates.
prnewswire.com
- 2 months ago
CalciMedica Secures Credit Facility for Up to $32.5 Million
$10 million funded at close extends cash runway into mid-2026 LA JOLLA, Calif. , March 5, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the Company has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P.
prnewswire.com
- 3 months ago
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference
62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo in subset of patients in CARDEA with AKI LA JOLLA, Calif. , March 4, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Sudarshan Hebbar, M.D.
prnewswire.com
- 3 months ago
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
LA JOLLA, Calif. , Feb. 19, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) being held March 3-6, 2025 in San Diego, CA.
prnewswire.com
- 3 months ago
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
LA JOLLA, Calif. , Feb. 3, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
prnewswire.com
- 4 months ago
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors
LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D.
prnewswire.com
- 5 months ago
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
LA JOLLA, Calif. , Nov. 21, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
prnewswire.com
- 6 months ago
CalciMedica Announces Presentations at Upcoming Medical Meetings
Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting LA JOLLA, Calif. , Nov. 20, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for plenary presentation at the American Pancreatic Association (APA) 2024 Annual Meeting being held December 9-10 in Maui, HI, and the acceptance of an abstract for poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting being held December 8-13 in Maui, HI.
prnewswire.com
- 6 months ago
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP); Company expects to be in a position to initiate Phase 3 program in 2025 Enrollment ongoing in Phase 2 KOURAGE trial in acute kidney injury (AKI) and in Phase 2 portion of CRSPA trial in asparaginase-induced pancreatic toxicity (AIPT); data from both trials expected in 2025 Following a public offering in October, the Company's cash position is expected to fund current operations into the first half of 2026 LA JOLLA, Calif. , Nov. 13, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2024 and provided clinical and corporate updates.
prnewswire.com
- 7 months ago
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
LA JOLLA, Calif. , Nov. 7, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Stephen Bardin as Chief Financial Officer and the planned departure of Daniel Geffken, Interim Chief Financial Officer upon filing the Company's third quarter financial statements.
prnewswire.com
- 7 months ago
8. Profile
Summary
CalciMedica, Inc. CALC
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 23.5 M
Dividend Yield
0.00%
Description
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Contact
505 Coast Boulevard South, La Jolla, CA, 92037
https://www.calcimedica.com
IPO
Date
June 14, 2023
Employees
14
Officers
Dr. Sudarshan Hebbar M.D.
Chief Medical Officer
Mr. Eric W. Roberts
Chief Business Officer & Vice Chairman of the Board
Mr. Michael J. Dunn M.B.A., MBA
President & Chief Operating Officer
Dr. Patrick Hogan Ph.D.
Co-Founder and Scientific Advisor
Dr. A. Rachel Leheny Ph.D.
Chief Executive Officer & Director
Dr. Kenneth A. Stauderman Ph.D.
Co-Founder & Chief Scientific Officer
Dr. Anjana Rao Ph.D.
Co-Founder and Scientific Advisor
Mr. Stephen B. Bardin
Chief Financial Officer
Dr. Stefan Feske M.D.
Co-Founder and Scientific Advisor
Mr. John M. Dunn J.D.
General Counsel